ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2024

May 20, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2024-05-14

Reporting Person: Wilson Martin (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-14	Common Stock	M	2420	—	Acquired	21100	Direct
2022-08-12	Common Stock	J	28763	—	Acquired	49863	Direct
2023-02-14	Common Stock	J	16947	—	Acquired	66810	Direct
2024-05-16	Common Stock	S	1048	$23.35	Disposed	65762	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-05-14	Restricted Stock Units	$	M	2420	Disposed		Common Stock (2420)	Direct
2022-08-12	Restricted Stock Units	$	J	28763	Disposed		Common Stock (28763)	Direct
2023-02-14	Restricted Stock Units	$	J	16947	Disposed		Common Stock (16947)	Direct

Footnotes

F1: Represents RSUs initially granted on February 14, 2023. One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years.

F2: Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs.

F3: Represents RSUs initially granted on August 12, 2022, which vest in full on August 12, 2025.

F4: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

F5: Each RSU represents a contingent right to receive one share of the Issuer's common stock.